Publication details
Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | Future Oncology |
| MU Faculty or unit | |
| Citation | |
| Web | http://dx.doi.org/10.2217/fon-2018-0934 |
| Doi | http://dx.doi.org/10.2217/fon-2018-0934 |
| Keywords | biomarkers; efficacy; pancreatic neuroendocrine tumor; sunitinib; VEGF |
| Description | Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes. |